Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

63.81USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$63.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,726
52-wk High
$68.98
52-wk Low
$21.95

Chart for

About

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone... (more)

Overall

Beta: --
Market Cap(Mil.): $1,304.09
Shares Outstanding(Mil.): 36.37
Dividend: --
Yield (%): --

Financials

BRIEF-Ascendis Pharma Reports Full Year 2017 Financial Results

* ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS

29 Mar 2018

BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

22 Feb 2018

BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS

* ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

21 Feb 2018

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

04 Jan 2018

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

21 Dec 2017

BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04

* Ascendis Pharma A/S reports third quarter 2017 financial results

17 Nov 2017

Competitors

Earnings vs. Estimates